Bruker Wins NIH and NSF-Funded NMR System Orders from NYSBC,

Bruker Wins NIH and NSF-Funded NMR System Orders from NYSBC, Delaware, and Northwestern

Bruker Corporation today announced the receipt of multiple new orders for its advanced Nuclear Magnetic Resonance (NMR) instrumentation from three leading U.S. research institutions — the New York Structural Biology Center (NYSBC), the University of Delaware, and Northwestern University. Supported…

Read MoreBruker Wins NIH and NSF-Funded NMR System Orders from NYSBC, Delaware, and Northwestern
FDA OKs Tecentriq + Lurbinectedin for First-Line Maintenance in ES-SCLC

FDA OKs Tecentriq + Lurbinectedin for First-Line Maintenance in ES-SCLC

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with lurbinectedin (Zepzelca®) for the maintenance treatment of adults with extensive-stage small…

Read MoreFDA OKs Tecentriq + Lurbinectedin for First-Line Maintenance in ES-SCLC